Epizyme (EPZM) Files $69M IPO

April 18, 2013 11:48 AM EDT
Epizyme (NASDAQ: EPZM) filed a $69 million IPO prospectus Thursday. The company plans to list on the The NASDAQ Global Market under the symbol "EPZM."

The IPO will be led by Citigroup, Cowen and Leerink Swann.

Epizyme is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers. The company systematically identify the genetic alterations that create cancer causing genes, called oncogenes, select patients in whom the identified genetic alteration is found and then design small molecule therapeutics to inhibit the oncogene. The clinical development plan for each of its product candidates is directed towards patients with a particular genetically defined cancer. Epizyme's approach is part of a broader trend towards personalized therapeutics based on first identifying the underlying cause of a disease afflicting specific patient populations, applying rational drug design tools to create a therapeutic to bind with a molecular target in the identified disease pathway and using a companion diagnostic to select the right patients for treatment.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

Citi, Cowen & Co

Add Your Comment